title: [One-week effects of Tamsulosin on benign prostatic hyperplasia assessed with a daily symptom score].
abstract: The early effects of Tamsulosin within one week of administration on lower urinary tract symptoms in patients with benign prostatic hyperplasia (BPH) were investigated. Patients with newly diagnosed BPH were randomized into a Tamsulosin group and a Eviprostat group. Changes in subjective symptoms daily for 7 days after the start of administration and in the 4th week (8 times in total) were evaluated using seven symptoms in the International Prostate Symptom Score (IPSS) and the quality of life (QOL) index entered in a self-scoring diary kept by the patients daily. In the Tamsulosin group, the IPSS total score showed significant improvements. Significant improvements were observed in the incomplete emptying and frequency scores from the day after the start of administration, in the intermittence and straining scores from day 2, in the urgency and weak stream scores from day 3 and in the nocturia score from day 5. The QOL index significantly improved on day 7. In comparison with Eviprostat, Tamsulosin showed a stronger improvement tendency in the total IPSS, voiding symptoms score and incomplete emptying score and the difference was significant. The difference between the two groups was especially marked for the intermittence and weak stream scores and Tamsulosin showed significantly better early effects. Tamsulosin also showed significantly better early effects than Eviprostat in the QOL index. In conclusion, it was clear that Tamsulosin caused significant improvement in lower urinary tract symptoms associated with BPH as a whole from a very early stage within one week after administration.
authors.affiliation: Department of Urology, Jikei University School of Medicine.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Tomita
authors.forename: Shin
authors.initials: S
authors.lastname: Egawa
authors.forename: Isao
authors.initials: I
authors.lastname: Ikemoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakajo
authors.forename: Takashi
authors.initials: T
authors.lastname: Hatano
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Kira
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Mizuo
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kagami
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000368:Aged; D004338:Drug Combinations; D004979:Ethamsylate / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008499:Medical Records; D010936:Plant Extracts / Q000008:administration & dosage; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D013449:Sulfonamides / Q000008:administration & dosage*; D000077409:Tamsulosin; D016055:Urinary Retention / Q000188:drug therapy
chemical_list: D000317:Adrenergic alpha-Antagonists; D004338:Drug Combinations; D010936:Plant Extracts; D013449:Sulfonamides; D004979:Ethamsylate; C010152:eviprostat; D000077409:Tamsulosin